[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.
7 Nov, 2021 | 20:35h | UTCCommentaries:
Pfizer’s Good News Is the World’s Good News – Science
Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT
Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP
Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC
Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press
Commentary on Twitter (thread – click for more)
Pfizer’s oral protease inhibitor PF-07321332 for #COVID19 Reduced Risk of Hospitalization or Death from 6.7% (41/612) to 1.0% (6/607) when starting within 5 days of symptom onset.
10 vs 0 deaths. #idtwitter https://t.co/ZAIm6Y5mAt— David Boulware, MD MPH (@boulware_dr) November 5, 2021